Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 placebo-Controlled, Double-Blind, Parallel-Group Study to Assess the Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease

Next Previous
Trial Profile

A phase 3 placebo-Controlled, Double-Blind, Parallel-Group Study to Assess the Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lecanemab (Primary) ; Traneurocin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 05 Aug 2024 According to a Biomed Industries media release, company announced combination therapy protocol for this trial at the Alzheimers Association International Conference (AAIC), held in Philadelphia, PA, from July 28 to August 1, 2024.
  • 01 Aug 2024 Trial design and protocol presented at the Alzheimer's Association International Conference 2024.
  • 09 Jul 2024 According to a Biomed Industries media release, clinical trial protocol of this trial will be presented at the Alzheimer's Association International Conference (AAIC) from July 28 to August 1, 2024, in Philadelphia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top